26 Chapter 2 Table 1: [continued] Study Author, year, country Design N operated VWD; (type VWD) Follow-up (months) Primary Outcome(s) Perioperative prophylaxis Bleeding complications - VWD% (N bleeding /N total) - Control%) Huq et al, 2011, United Kingdom15 Retrospective cohort 5 (NR) 32 (6-76) months Physician reported bleeding complications, satisfaction (questionnaire not specified) TA, DDAVP None occurred Baggish et al, 1997, USA13 Retrospective cohort 1 (NR) 54 (12-120) months Physician reported bleeding complications Plasma None occurred Alesci S et al, 2012, Germany20 Retrospective cohort 7 ( type 1, type 2A, type 2N, acquired) NR Physician reported bleeding complications VWF/FVIII concentrate None occurred Halimeh S et al, 2012, Germany18 Retrospective cohort 7 (type 1, type 3) NR Physician reported bleeding complications TA None occurred (N number, NR Not Reported, HMB Heavy menstrual bleeding, VWF Von Willebrand factor, DDAVP desmopressin, VWD von Willebrand Disease ; TA tranexamic acid).
RkJQdWJsaXNoZXIy MTk4NDMw